Erasca, Inc. ERAS
15.70 USD -1.10 (-6.55%)
Nov 12, 2026, 2:38 PM EST
15.16 Day range 16.22
2.46 52-week range 24.28
- YTD
- +322.04%
- 1 year
- +492.45%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
benzinga.com B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20 B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises the price target from $18 to $20.
benzinga.com Guggenheim Maintains Buy on Erasca, Raises Price Target to $21 Guggenheim analyst Paul Jeng maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $20 to $21.- benzinga.com HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $18 to $22.
benzinga.com Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12)…
benzinga.com Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21 Morgan Stanley analyst Sean Laaman maintains Erasca (NASDAQ:ERAS) with a Equal-Weight and raises the price target from $12 to $21.
benzinga.com Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.- benzinga.com B of A Securities Maintains Neutral on Erasca, Raises Price Target to $18 B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises the price target from $16 to $18.
benzinga.com Erasca Plans To Commence $500M Common Stock Offering Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers,…
benzinga.com Erasca Announces Updated Preliminary ERAS‑0015 Phase 1 Data And Clinical Plans, With Pivotal Lung And Pancreatic Cancer Trials Slated For 2027 At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100%Monotherapy has been generally…
benzinga.com This KeyBanc Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Top analysts upgrade MUR, UNH, ESNT, and ERAS stocks. For more rating changes, see analyst ratings page. See what analysts think of UNH stock.
benzinga.com B of A Securities Upgrades Erasca to Neutral, Raises Price Target to $16 B of A Securities analyst Alec Stranahan upgrades Erasca (NASDAQ:ERAS) from Underperform to Neutral and raises the price target from $9 to $16.
benzinga.com Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.- benzinga.com Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26 Mizuho analyst Joseph Catanzaro maintains Erasca (NASDAQ:ERAS) with a Outperform and lowers the price target from $28 to $26.
- benzinga.com Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.22) by 172.73 percent. This is a 445.45 percent decrease over losses of $(0.11)…
- benzinga.com Erasca Announces Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate ERAS-0015 In Combination With Keytruda This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Crude Oil Gains Over 3%; General Motors Earnings Top Views US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0.65%. GM reports better-than-expected Q1 results.
benzinga.com CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
benzinga.com Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63%,…
benzinga.com Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines' patent and trade secret allegations.
benzinga.com Rambus Posts Downbeat Q1 Earnings, Joins Erasca, Spotify, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures mixed, Nasdaq down 1%. Rambus Inc (NASDAQ: RMBS) shares fall 15.1% pre-market after reporting mixed Q1 results. Other stocks also down.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Bed Bath & Beyond Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket Shares of Bed Bath & Beyond (BBBY) rose 23.4% in pre-market trading after beating revenue estimates. KIDZ, CLDI, DRCT, PFSA, KFRC, MLEC, SANM, SEI, DT are also up while VISN, ERAS, AREB, and YAAS are…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Erasca Reports Early Phase 1 Results For ERAS-0015 With High Response Rates In KRAS-Mutant Lung And Pancreatic Cancers Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDERobust monotherapy efficacy in 2L KRAS…
- benzinga.com Revolution Medicines Alleges Patent, Trade Secret, And False Comparison Claims Over ERAS-0015; Erasca Vows Strong Defense On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed"). In the letter RevMed alleged that (1) the Company's asset ERAS-0015 is "substantially…
- benzinga.com Erasca To Host Conference Call To Discuss Preliminary Phase 1 Dose Escalation Data For Pan-RAS Molecular Glue ERAS-0015 In Patients With RAS-Mutant Solid Tumors On April 27 Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers,…
- benzinga.com Stifel Maintains Buy on Erasca, Raises Price Target to $30 Stifel analyst Laura Prendergast maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $20 to $30.
benzinga.com Erasca Narrows ERAS-0015 Phase 1 Data Readout Timeline To Mid-May 2026 On April 21, 2026, Erasca, Inc. (the "Company") narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company's pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and…
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…- benzinga.com JP Morgan Maintains Overweight on Erasca, Raises Price Target to $25 JP Morgan analyst Anupam Rama maintains Erasca (NASDAQ:ERAS) with a Overweight and raises the price target from $24 to $25.
- benzinga.com Guggenheim Maintains Buy on Erasca, Raises Price Target to $20 Guggenheim analyst Michael Schmidt maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $12 to $20.
- benzinga.com Piper Sandler Maintains Overweight on Erasca, Raises Price Target to $18 Piper Sandler analyst Kelsey Goodwin maintains Erasca (NASDAQ:ERAS) with a Overweight and raises the price target from $11 to $18.
- benzinga.com Mizuho Maintains Outperform on Erasca, Raises Price Target to $19 Mizuho analyst Joseph Catanzaro maintains Erasca (NASDAQ:ERAS) with a Outperform and raises the price target from $16 to $19.
benzinga.com FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday Top Wall Street analysts changed outlook on top names: Adobe cut to $280, ServiceTitan to $100, KinderCare cut to $1.5, Nio upgraded to $6.8, Esperion raised to $5, Flagstar raised to $16, Nerdwallet…- benzinga.com HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $20 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $15 to $20.
- benzinga.com Erasca Q4 EPS $(0.10), Inline Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period…
benzinga.com Erasca Expands Joyo Pharmatech License To China, Hong Kong, And Macau, Securing Worldwide Rights To pan-RAS Molecular Glue ERAS-0015 Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategyERAS-0015's promising early clinical data underscore its potential to be a best-in-class…
benzinga.com Okta To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, visit our analyst ratings page. B of A…- benzinga.com Clear Street Maintains Buy on Erasca, Raises Price Target to $20 Clear Street analyst Kaveri Pohlman maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $11 to $20.
- benzinga.com Erasca Secures U.S. Patent Titled Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043Expands Erasca's diversified IP portfolio for RAS-driven cancersInitial Phase 1…
benzinga.com Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? Erasca stock fell Monday despite no company news, after reports said Merck ended acquisition talks with cancer drugmaker Revolution Medicines over valuation differences.- benzinga.com HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $15 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $11 to $15.
benzinga.com Benzinga Bulls And Bears: Netflix, Capital One, Intuitive Surgical — And Markets Ride Greenland Roller Coaster Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
benzinga.com Top 2 Materials Stocks That May Crash In Q1 
benzinga.com Top 2 Tech Stocks That Are Ticking Portfolio Bombs